The Experts below are selected from a list of 40494 Experts worldwide ranked by ideXlab platform
Christine G Lian - One of the best experts on this subject based on the ideXlab platform.
-
5 hydroxymethylcytosine expression in metastatic melanoma versus nodal nevus in Sentinel Lymph Node biopsies
Modern Pathology, 2015Co-Authors: Scott R Granter, Alvaro C Laga, Arturo P Saavedra, Qian Zhan, Shuyun Xu, George F Murphy, Christine G LianAbstract:Sentinel Lymph Node biopsies are conducted to stage patients with newly-diagnosed melanomas that have histopathologic attributes conferring defined levels of metastatic potential. Because benign nevic cells may also form ‘deposits’ in Lymph Nodes (nodal nevus), the pathologic evaluation for metastatic melanoma within Sentinel Lymph Nodes can be challenging. 28 Sentinel Lymph Node biopsy cases containing either metastatic melanoma (N=18) or nodal nevi (N=10) were retrieved from the archives of the Brigham and Women’s Hospital Department of Pathology (2011–2014). In addition, two Sentinel Lymph Node cases that were favored to represent metastatic disease but whose histopathologic features were viewed as equivocal, with melanoma favored, were also included. Dual-labeling for the melanocyte lineage marker, MART-1, and the epigenetic marker 5-hydroxymethylcytosine, a functionally-significant indicator that has been shown to distinguish benign nevi from melanoma, was performed on all cases using immunohistochemistry and/or direct immunofluorescence. All (18 of 18) metastatic melanoma cases showed complete loss of 5-hydroxymethylcytosine nuclear staining in MART-1-positive cells and all (10 of 10) nodal nevus cases demonstrated 5-hydroxymethylcytosine nuclear staining in MART-1 positive cells. In addition, 5-hydroxymethylcytosine staining confirmed the favored diagnoses of metastatic melanoma in the two ‘equivocal’ cases. Thus, 5-hydroxymethylcytosine may be a useful adjunctive marker to distinguish between benign nodal nevi and metastatic melanoma during the evaluation of Sentinel Lymph Node biopsies for metastatic melanoma.
-
5-Hydroxymethylcytosine expression in metastatic melanoma versus nodal nevus in Sentinel Lymph Node biopsies
Modern Pathology, 2015Co-Authors: Scott R Granter, Alvaro C Laga, Arturo P Saavedra, Qian Zhan, Shuyun Xu, George F Murphy, Christine G LianAbstract:Sentinel Lymph Node biopsies are conducted to stage patients with newly diagnosed melanomas that have histopathological attributes conferring defined levels of metastatic potential. Because benign nevic cells may also form ‘deposits’ in Lymph Nodes (nodal nevus), the pathological evaluation for metastatic melanoma within Sentinel Lymph Nodes can be challenging. Twenty-eight Sentinel Lymph Node biopsy cases containing either metastatic melanoma ( N =18) or nodal nevi ( N =10) were retrieved from the archives of the Brigham and Women’s Hospital, Department of Pathology (2011–2014). In addition, two Sentinel Lymph Node cases that were favored to represent metastatic disease but whose histopathological features were viewed as equivocal, with melanoma favored, were also included. Dual labeling for the melanocyte lineage marker, MART-1, and the epigenetic marker, 5-hydroxymethylcytosine, a functionally significant indicator that has been shown to distinguish benign nevi from melanoma, was performed on all cases using immunohistochemistry and/or direct immunofluorescence. All (18 of 18) metastatic melanoma cases showed complete loss of 5-hydroxymethylcytosine nuclear staining in MART-1-positive cells, and all (10 of 10) nodal nevus cases demonstrated 5-hydroxymethylcytosine nuclear staining in MART-1-positive cells. In addition, 5-hydroxymethylcytosine staining confirmed the favored diagnoses of metastatic melanoma in the two ‘equivocal’ cases. Thus, 5-hydroxymethylcytosine may be a useful adjunctive marker to distinguish between benign nodal nevi and metastatic melanoma during the evaluation of Sentinel Lymph Node biopsies for metastatic melanoma.
Arturo P Saavedra - One of the best experts on this subject based on the ideXlab platform.
-
5 hydroxymethylcytosine expression in metastatic melanoma versus nodal nevus in Sentinel Lymph Node biopsies
Modern Pathology, 2015Co-Authors: Scott R Granter, Alvaro C Laga, Arturo P Saavedra, Qian Zhan, Shuyun Xu, George F Murphy, Christine G LianAbstract:Sentinel Lymph Node biopsies are conducted to stage patients with newly-diagnosed melanomas that have histopathologic attributes conferring defined levels of metastatic potential. Because benign nevic cells may also form ‘deposits’ in Lymph Nodes (nodal nevus), the pathologic evaluation for metastatic melanoma within Sentinel Lymph Nodes can be challenging. 28 Sentinel Lymph Node biopsy cases containing either metastatic melanoma (N=18) or nodal nevi (N=10) were retrieved from the archives of the Brigham and Women’s Hospital Department of Pathology (2011–2014). In addition, two Sentinel Lymph Node cases that were favored to represent metastatic disease but whose histopathologic features were viewed as equivocal, with melanoma favored, were also included. Dual-labeling for the melanocyte lineage marker, MART-1, and the epigenetic marker 5-hydroxymethylcytosine, a functionally-significant indicator that has been shown to distinguish benign nevi from melanoma, was performed on all cases using immunohistochemistry and/or direct immunofluorescence. All (18 of 18) metastatic melanoma cases showed complete loss of 5-hydroxymethylcytosine nuclear staining in MART-1-positive cells and all (10 of 10) nodal nevus cases demonstrated 5-hydroxymethylcytosine nuclear staining in MART-1 positive cells. In addition, 5-hydroxymethylcytosine staining confirmed the favored diagnoses of metastatic melanoma in the two ‘equivocal’ cases. Thus, 5-hydroxymethylcytosine may be a useful adjunctive marker to distinguish between benign nodal nevi and metastatic melanoma during the evaluation of Sentinel Lymph Node biopsies for metastatic melanoma.
-
5-Hydroxymethylcytosine expression in metastatic melanoma versus nodal nevus in Sentinel Lymph Node biopsies
Modern Pathology, 2015Co-Authors: Scott R Granter, Alvaro C Laga, Arturo P Saavedra, Qian Zhan, Shuyun Xu, George F Murphy, Christine G LianAbstract:Sentinel Lymph Node biopsies are conducted to stage patients with newly diagnosed melanomas that have histopathological attributes conferring defined levels of metastatic potential. Because benign nevic cells may also form ‘deposits’ in Lymph Nodes (nodal nevus), the pathological evaluation for metastatic melanoma within Sentinel Lymph Nodes can be challenging. Twenty-eight Sentinel Lymph Node biopsy cases containing either metastatic melanoma ( N =18) or nodal nevi ( N =10) were retrieved from the archives of the Brigham and Women’s Hospital, Department of Pathology (2011–2014). In addition, two Sentinel Lymph Node cases that were favored to represent metastatic disease but whose histopathological features were viewed as equivocal, with melanoma favored, were also included. Dual labeling for the melanocyte lineage marker, MART-1, and the epigenetic marker, 5-hydroxymethylcytosine, a functionally significant indicator that has been shown to distinguish benign nevi from melanoma, was performed on all cases using immunohistochemistry and/or direct immunofluorescence. All (18 of 18) metastatic melanoma cases showed complete loss of 5-hydroxymethylcytosine nuclear staining in MART-1-positive cells, and all (10 of 10) nodal nevus cases demonstrated 5-hydroxymethylcytosine nuclear staining in MART-1-positive cells. In addition, 5-hydroxymethylcytosine staining confirmed the favored diagnoses of metastatic melanoma in the two ‘equivocal’ cases. Thus, 5-hydroxymethylcytosine may be a useful adjunctive marker to distinguish between benign nodal nevi and metastatic melanoma during the evaluation of Sentinel Lymph Node biopsies for metastatic melanoma.
Hans-martin Häfner - One of the best experts on this subject based on the ideXlab platform.
-
Sentinel Lymph Node biopsy for high-thickness cutaneous squamous cell carcinoma
Archives of Dermatological Research, 2020Co-Authors: Lukas Kofler, Katrin Kofler, Claudia Schulz, Helmut Breuninger, Hans-martin HäfnerAbstract:Squamous cell carcinomas are among the most common skin tumors and show a risk of metastasis depending on various factors such as tumor thickness, localization, histological subtype and immune status of the patient. Sentinel Lymph Node biopsy (SLNB) SLNB represents a possibility for assessing the locoregional Lymph Node status. In this study, the role of the SLNB in Lymph Node status and survival was analyzed. Retrospectively, 720 patients with high-risk squamous cell carcinoma (tumor thickness > 5 mm) were examined. 150 patients agreed to SLNB, 570 patients did not undergo histologic confirmation of Lymph Node status and were included directly in follow-up. In 101 patients, a Sentinel Lymph Node was successfully marked and extirpated, followed by regular follow-up examinations. A total of 11.11% of the patients showed Lymph Node metastasis in the course of their treatment, with no difference in the proportion of patients in the SLNB group (11.9%) and the observation group (11.4%) ( p = 0.873). The proportion of distant metastasis also did not differ between the groups ( p = 0.898). In 3.96% of the patients in the SLNB group, a metastasis was found in the Sentinel Lymph Node. Tumor-specific death was observed in 7.14% of the patients in the SLNB group and 4.74% in the observation group ( p = 0.269). Although SLNB is a principally suitable method for determining Lymph Node status, the available data do not provide any benefit regarding further metastasis or tumor-specific survival.
Scott R Granter - One of the best experts on this subject based on the ideXlab platform.
-
5 hydroxymethylcytosine expression in metastatic melanoma versus nodal nevus in Sentinel Lymph Node biopsies
Modern Pathology, 2015Co-Authors: Scott R Granter, Alvaro C Laga, Arturo P Saavedra, Qian Zhan, Shuyun Xu, George F Murphy, Christine G LianAbstract:Sentinel Lymph Node biopsies are conducted to stage patients with newly-diagnosed melanomas that have histopathologic attributes conferring defined levels of metastatic potential. Because benign nevic cells may also form ‘deposits’ in Lymph Nodes (nodal nevus), the pathologic evaluation for metastatic melanoma within Sentinel Lymph Nodes can be challenging. 28 Sentinel Lymph Node biopsy cases containing either metastatic melanoma (N=18) or nodal nevi (N=10) were retrieved from the archives of the Brigham and Women’s Hospital Department of Pathology (2011–2014). In addition, two Sentinel Lymph Node cases that were favored to represent metastatic disease but whose histopathologic features were viewed as equivocal, with melanoma favored, were also included. Dual-labeling for the melanocyte lineage marker, MART-1, and the epigenetic marker 5-hydroxymethylcytosine, a functionally-significant indicator that has been shown to distinguish benign nevi from melanoma, was performed on all cases using immunohistochemistry and/or direct immunofluorescence. All (18 of 18) metastatic melanoma cases showed complete loss of 5-hydroxymethylcytosine nuclear staining in MART-1-positive cells and all (10 of 10) nodal nevus cases demonstrated 5-hydroxymethylcytosine nuclear staining in MART-1 positive cells. In addition, 5-hydroxymethylcytosine staining confirmed the favored diagnoses of metastatic melanoma in the two ‘equivocal’ cases. Thus, 5-hydroxymethylcytosine may be a useful adjunctive marker to distinguish between benign nodal nevi and metastatic melanoma during the evaluation of Sentinel Lymph Node biopsies for metastatic melanoma.
-
5-Hydroxymethylcytosine expression in metastatic melanoma versus nodal nevus in Sentinel Lymph Node biopsies
Modern Pathology, 2015Co-Authors: Scott R Granter, Alvaro C Laga, Arturo P Saavedra, Qian Zhan, Shuyun Xu, George F Murphy, Christine G LianAbstract:Sentinel Lymph Node biopsies are conducted to stage patients with newly diagnosed melanomas that have histopathological attributes conferring defined levels of metastatic potential. Because benign nevic cells may also form ‘deposits’ in Lymph Nodes (nodal nevus), the pathological evaluation for metastatic melanoma within Sentinel Lymph Nodes can be challenging. Twenty-eight Sentinel Lymph Node biopsy cases containing either metastatic melanoma ( N =18) or nodal nevi ( N =10) were retrieved from the archives of the Brigham and Women’s Hospital, Department of Pathology (2011–2014). In addition, two Sentinel Lymph Node cases that were favored to represent metastatic disease but whose histopathological features were viewed as equivocal, with melanoma favored, were also included. Dual labeling for the melanocyte lineage marker, MART-1, and the epigenetic marker, 5-hydroxymethylcytosine, a functionally significant indicator that has been shown to distinguish benign nevi from melanoma, was performed on all cases using immunohistochemistry and/or direct immunofluorescence. All (18 of 18) metastatic melanoma cases showed complete loss of 5-hydroxymethylcytosine nuclear staining in MART-1-positive cells, and all (10 of 10) nodal nevus cases demonstrated 5-hydroxymethylcytosine nuclear staining in MART-1-positive cells. In addition, 5-hydroxymethylcytosine staining confirmed the favored diagnoses of metastatic melanoma in the two ‘equivocal’ cases. Thus, 5-hydroxymethylcytosine may be a useful adjunctive marker to distinguish between benign nodal nevi and metastatic melanoma during the evaluation of Sentinel Lymph Node biopsies for metastatic melanoma.
Dongyeon Park - One of the best experts on this subject based on the ideXlab platform.
-
high foxp3 regulatory t cell density in the Sentinel Lymph Node is associated with downstream non Sentinel Lymph Node metastasis in gastric cancer
British Journal of Cancer, 2011Co-Authors: Dongyeon ParkAbstract:High FOXP3+ regulatory T-cell density in the Sentinel Lymph Node is associated with downstream non-Sentinel Lymph-Node metastasis in gastric cancer
